These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 25850430)

  • 41. [Cognitive assessment of asymptomatic Huntington's disease carriers].
    Gómez-Tortosa E; del Barrio Alba A; Sánchez Pernaute R; Benítez J; Barroso A; García Yébenes J
    Neurologia; 1997; 12(6):226-31. PubMed ID: 9303588
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning.
    Reedeker N; Van Der Mast RC; Giltay EJ; Van Duijn E; Roos RA
    Mov Disord; 2010 Aug; 25(11):1612-8. PubMed ID: 20629165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of two brief screening measures of cognitive impairment in Huntington's disease.
    Mickes L; Jacobson M; Peavy G; Wixted JT; Lessig S; Goldstein JL; Corey-Bloom J
    Mov Disord; 2010 Oct; 25(13):2229-33. PubMed ID: 20721924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intellectual Curiosity and Action Initiation are Subtypes of Apathy Affected in Huntington Disease Gene Expansion Carriers.
    Hendel RK; Hellem MNN; Hjermind LE; Nielsen JE; Vogel A
    Cogn Behav Neurol; 2021 Dec; 34(4):295-302. PubMed ID: 34851867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of the frontal assessment battery in evaluating executive dysfunction in patients with Huntington's disease.
    Rodrigues GR; Souza CP; Cetlin RS; de Oliveira DS; Pena-Pereira M; Ujikawa LT; Marques W; Tumas V
    J Neurol; 2009 Nov; 256(11):1809-15. PubMed ID: 19536583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease.
    Begeti F; Tan AY; Cummins GA; Collins LM; Guzman NV; Mason SL; Barker RA
    J Neurol; 2013 Nov; 260(11):2777-85. PubMed ID: 23922130
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Altered frontostriatal coupling in pre-manifest Huntington's disease: effects of increasing cognitive load.
    Wolf RC; Sambataro F; Vasic N; Schönfeldt-Lecuona C; Ecker D; Landwehrmeyer B
    Eur J Neurol; 2008 Nov; 15(11):1180-90. PubMed ID: 18754766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Speech biomarkers in Huntington's disease: A cross-sectional study in pre-symptomatic, prodromal and early manifest stages.
    Kouba T; Frank W; Tykalova T; Mühlbäck A; Klempíř J; Lindenberg KS; Landwehrmeyer GB; Rusz J
    Eur J Neurol; 2023 May; 30(5):1262-1271. PubMed ID: 36732902
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Defective emotion recognition in early HD is neuropsychologically and anatomically generic.
    Henley SM; Wild EJ; Hobbs NZ; Warren JD; Frost C; Scahill RI; Ridgway GR; MacManus DG; Barker RA; Fox NC; Tabrizi SJ
    Neuropsychologia; 2008; 46(8):2152-60. PubMed ID: 18407301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Variability in cognitive function among persons at high genetic risk of Huntington's disease.
    Lundervold AJ; Reinvang I
    Acta Neurol Scand; 1995 Jun; 91(6):462-9. PubMed ID: 7572041
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease.
    Andrews SC; Craufurd D; Durr A; Leavitt BR; Roos RA; Tabrizi SJ; Stout JC
    Neuropsychology; 2018 Nov; 32(8):958-965. PubMed ID: 30211612
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.
    Stout JC; Jones R; Labuschagne I; O'Regan AM; Say MJ; Dumas EM; Queller S; Justo D; Santos RD; Coleman A; Hart EP; Dürr A; Leavitt BR; Roos RA; Langbehn DR; Tabrizi SJ; Frost C
    J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):687-94. PubMed ID: 22566599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mild cognitive impairment and dementia in motor manifest Huntington's disease: Classification and prevalence.
    Julayanont P; McFarland NR; Heilman KM
    J Neurol Sci; 2020 Jan; 408():116523. PubMed ID: 31678902
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy.
    Scahill RI; Hobbs NZ; Say MJ; Bechtel N; Henley SM; Hyare H; Langbehn DR; Jones R; Leavitt BR; Roos RA; Durr A; Johnson H; Lehéricy S; Craufurd D; Kennard C; Hicks SL; Stout JC; Reilmann R; Tabrizi SJ;
    Hum Brain Mapp; 2013 Mar; 34(3):519-29. PubMed ID: 22102212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening for cognitive dysfunction in Huntington's disease with the clock drawing test.
    Terwindt PW; Hubers AA; Giltay EJ; van der Mast RC; van Duijn E
    Int J Geriatr Psychiatry; 2016 Sep; 31(9):1013-20. PubMed ID: 26766850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Seven-year clinical follow-up of premanifest carriers of Huntington's disease.
    Hart E; Middelkoop H; Jurgens CK; Witjes-Ané MN; Roos RA
    PLoS Curr; 2011 Nov; 3():RRN1288. PubMed ID: 22173894
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
    ; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
    JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease.
    Aziz NA; Anguelova GV; Marinus J; Lammers GJ; Roos RA
    Parkinsonism Relat Disord; 2010 Jun; 16(5):345-50. PubMed ID: 20236854
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mentalizing in preclinical Huntington's disease: an fMRI study using cartoon picture stories.
    Saft C; Lissek S; Hoffmann R; Nicolas V; Tegenthoff M; Juckel G; Brüne M
    Brain Imaging Behav; 2013 Jun; 7(2):154-62. PubMed ID: 23179063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resting-state fMRI reveals potential neural correlates of impaired cognition in Huntington's disease.
    Liu W; Yang J; Chen K; Luo C; Burgunder J; Gong Q; Shang H
    Parkinsonism Relat Disord; 2016 Jun; 27():41-6. PubMed ID: 27117563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.